Health
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates – News-Medical.net
Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences,…
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore…
Continue Reading
